Oxford BioDynamics

Oxford BioDynamics PLC (OBD) commercializes EpiSwitch 3D gene regulation for precision medicine. Its portfolio of clinical smart tests based on EpiSwitch technology aims to help people face challenging health decisions with confidence and tackle rising healthcare costs. The company partners with state-of-the-art CLIA-certified commercial labs to deliver clinical tests to physicians. Its tests include EpiSwitch PSE, a prostate cancer detection test administered alongside or following a standard PSA test; EpiSwitch CiRT, a first-of-its-kind blood test to predict patient response to immune checkpoint inhibitor therapies; and EpiSwitch ME/CFS, a first-in-class test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. The company is based in Oxford, United Kingdom.

Oxford BioDynamics PLC commercializes EpiSwitch 3D gene regulation for precision medicine. Its portfolio of clinical smart tests based on EpiSwitch technology aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare. The company partners with state-of-the-art CLIA-certified commercial labs to rapidly deliver clinical tests into the hands of physicians helping to inform a treatment plan tailored for their patients. Its tests include EpiSwitch PSE, a prostate cancer detection test administered alongside or following a standard PSA test; EpiSwitch CiRT, a first-of-its-kind blood test to predict patient response to immune checkpoint inhibitor therapies; and EpiSwitch ME/CFS, a first-in-class test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. The company is based in Oxford, United Kingdom.

Commercializing EpiSwitch 3D gene regulation for precision medicine; clinical smart tests based on EpiSwitch technology.

• EpiSwitch PSE

  A prostate cancer detection test that identifies an individual's current likelihood of prostate cancer from blood with 94% accuracy. It is administered alongside or following a standard PSA test to significantly boost detection performance and reduce the number of men referred for unnecessary biopsies and treatments.

• EpiSwitch CiRT

  A first-of-its-kind blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. It provides patient-specific guidance to support informed decision-making regarding treatment plans.

• EpiSwitch ME/CFS

  A first-in-class test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. In development, it demonstrated 96% accuracy in detecting the condition.

1. 1Oxford BioDynamics PLC (OBD)oxfordbiodynamics.com
2. 2Oxford BioDynamics :: EpiSwitch® CiRTmycirt.com
3. 3Products & Services :: Oxford BioDynamics PLC (OBD)oxfordbiodynamics.com
4. 4Specimen Submission Kit :: Oxford BioDynamics PLC (OBD)oxfordbiodynamics.com
5. 5Oxford BioDynamics (United Kingdom)wikidata.org
6. 6Oxford BioDynamics Plc: Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch Explorer Array Kit for R&D usefinanznachrichten.de